Modeling and simulation offer useful predictions that can help guide your drug development program—but what if you could get even more out of the available technology?
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions
Over the past few years, PBPK and PBBM modelling have proven their significance in drug development. PBPK modelling is traditionally used to predict..
Development of Successful Physiologically-Based Pharmacokinetic (PBPK) Models
Physiologically-based pharmacokinetic (PBPK) modeling is a strong mathematical tool that integrates body physiology, drug physicochemical properties...
In silico modeling-based new alternative methods to predict drug and herb-induced liver injury: A review
New approach methods (NAMs) have been developed to predict a wide range of toxicities through innovative technologies.
Teaching of Drug Disposition using Physiologically Based Pharmacokinetic Modeling Software: GastroPlus as an Educational Tool
Physiologically based pharmacokinetic (PBPK) modeling requires understanding of chemical, physiologic, and pharmacokinetic principles.
Structural insights into the interaction of three Y-shaped ligands with PI3Kα
Class IA phosphoinositide 3-kinase alpha (PI3Kα) is an important drug target because it is one of the most frequently mutated proteins in human cancers.
Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space
The use of physiologically based biopharmaceutics modeling (PBBM) and bioequivalence safe space is increasingly common for immediate-release drug products.
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
Physiologically based pharmacokinetics (PBPK) models are increasingly used in the drug research and development, especially in anti-cancer drugs.
Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
Coupling biorelevant in vitro dissolution with in silico physiological-based pharmacokinetic (PBPK) tools represents a promising method to describe...
Best Practices for Data Visualisation
Best Practices for Data Visualisation (for the Royal Statistical Society) contains insights, advice, and examples (with code) to make data outputs more impactful.
Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions
Index substrates and inhibitors to investigate the role of the polymorphic enzyme, cytochrome P450 (CYP) 2D6, in the metabolism of new compounds have been proposed by regulatory agencies.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF).
Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary
Due to the strong tendency towards poorly soluble drugs in modern development pipelines, enabling drug formulations such as amorphous solid dispersions...
Simulations Plus Releases ADMET Predictor® 11
New functionality, models, and partner data power predictive accuracy from the industry-leading machine learning platform
Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes in Cannabis sativa
Cannabis sativa is a plant used for recreational and therapeutic purposes; however, many of the secondary metabolites in the plant have not been thoroughly investigated.
July 2023 GastroPlus Newsletter
GastroPlus® Newsletter July 2023
Projection of Target Drug Particle Size in Oral Formulations Using the Refined Developability Classification System (rDCS)
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall.
